This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Q2 FY27 revenue up 31.4%, profit after tax up 55.8%; results restated after merger
AGARWALEYE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.5 pts more than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Consolidated Q2 FY27 revenue was INR 655.46 crore, up 31.4% from INR 498.69 crore in Q2 FY26; profit after tax rose 55.8% to INR 56.85 crore from INR 36.49 crore, while EBITDA rose 28.8% to INR 185.56 crore. EBITDA margin eased to 27.9% from 28.4%. Consolidated H1 FY27 revenue was INR 1,269.48 crore, up 28.7%, and profit after tax INR 111.87 crore, up 50.1%. Comparatives were restated after the merger; 15.19 million new shares are pending.
Strong quarterly growth may support the stock, but 15.19 million new merger shares may dilute holders and the chairman appointment awaits votes.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹655.5 Cr | ₹498.7 Cr | +31.4% |
| Operating profit | ₹70.14 Cr | ₹45.73 Cr | +53.4% |
| Profit after tax | ₹56.85 Cr | ₹36.49 Cr | +55.8% |
| EBITDA margin | 26.8% | 27.3% | −0.5 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.